These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 19737541

  • 1. ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.
    Ugarenko M, Nudelman A, Rephaeli A, Kimura K, Phillips DR, Cutts SM.
    Biochem Pharmacol; 2010 Feb 01; 79(3):339-49. PubMed ID: 19737541
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
    Lieber J, Kirchner B, Eicher C, Warmann SW, Seitz G, Fuchs J, Armeanu-Ebinger S.
    Pediatr Blood Cancer; 2010 Dec 01; 55(6):1089-95. PubMed ID: 20680965
    [Abstract] [Full Text] [Related]

  • 3. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
    Swift LP, Cutts SM, Nudelman A, Levovich I, Rephaeli A, Phillips DR.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(5):739-49. PubMed ID: 17594094
    [Abstract] [Full Text] [Related]

  • 4. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
    High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, Vikstrom IB, Roberts AW, Lock RB.
    Mol Pharmacol; 2010 Mar 01; 77(3):483-94. PubMed ID: 20038611
    [Abstract] [Full Text] [Related]

  • 5. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A.
    Clin Cancer Res; 2007 Dec 01; 13(23):7191-8. PubMed ID: 18056200
    [Abstract] [Full Text] [Related]

  • 6. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.
    Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Böck BC, Macher-Goeppinger S, Radlwimmer B, Wiestler OD, Herold-Mende C, Roth W.
    Oncogene; 2008 Nov 06; 27(52):6646-56. PubMed ID: 18663354
    [Abstract] [Full Text] [Related]

  • 7. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
    Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP.
    J Natl Cancer Inst; 2008 Apr 16; 100(8):580-95. PubMed ID: 18398104
    [Abstract] [Full Text] [Related]

  • 8. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
    Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, Schlossman R, Ghobrial I, Raje N, Munshi N, Anderson KC.
    Oncogene; 2007 Apr 05; 26(16):2374-80. PubMed ID: 17016430
    [Abstract] [Full Text] [Related]

  • 9. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T.
    Br J Haematol; 2008 Jan 05; 140(2):181-90. PubMed ID: 18028486
    [Abstract] [Full Text] [Related]

  • 10. ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress.
    Howard AN, Bridges KA, Meyn RE, Chandra J.
    Cancer Chemother Pharmacol; 2009 Dec 05; 65(1):41-54. PubMed ID: 19404643
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
    Lee SJ, Park HJ, Kim YH, Kim BY, Jin HS, Kim HJ, Han JH, Yim H, Jeong SY.
    Int J Mol Med; 2012 Aug 05; 30(2):443-50. PubMed ID: 22664653
    [Abstract] [Full Text] [Related]

  • 12. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics.
    Karlberg M, Ekoff M, Huang DC, Mustonen P, Harvima IT, Nilsson G.
    J Immunol; 2010 Aug 15; 185(4):2555-62. PubMed ID: 20639495
    [Abstract] [Full Text] [Related]

  • 13. Targeting multiple arms of the apoptotic regulatory machinery.
    Dai Y, Grant S.
    Cancer Res; 2007 Apr 01; 67(7):2908-11. PubMed ID: 17409392
    [Abstract] [Full Text] [Related]

  • 14. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
    Trudel S, Stewart AK, Li Z, Shu Y, Liang SB, Trieu Y, Reece D, Paterson J, Wang D, Wen XY.
    Clin Cancer Res; 2007 Jan 15; 13(2 Pt 1):621-9. PubMed ID: 17255285
    [Abstract] [Full Text] [Related]

  • 15. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
    Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM.
    Cancer Res; 2006 May 01; 66(9):4863-71. PubMed ID: 16651442
    [Abstract] [Full Text] [Related]

  • 16. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
    Russo M, Spagnuolo C, Volpe S, Tedesco I, Bilotto S, Russo GL.
    Biochem Pharmacol; 2013 Apr 01; 85(7):927-36. PubMed ID: 23353698
    [Abstract] [Full Text] [Related]

  • 17. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
    Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M.
    Cancer Cell; 2006 Nov 01; 10(5):375-88. PubMed ID: 17097560
    [Abstract] [Full Text] [Related]

  • 18. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, Fesik SW, Shen Y.
    Oncogene; 2007 Jun 07; 26(27):3972-9. PubMed ID: 17173063
    [Abstract] [Full Text] [Related]

  • 19. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
    Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, Martineau D, McClellan WJ, Mitten M, Ng SC, Nimmer PM, Oltersdorf T, Park CM, Petros AM, Shoemaker AR, Song X, Wang X, Wendt MD, Zhang H, Fesik SW, Rosenberg SH, Elmore SW.
    J Med Chem; 2007 Feb 22; 50(4):641-62. PubMed ID: 17256834
    [Abstract] [Full Text] [Related]

  • 20. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.
    Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, Greipp PR, Kumar S.
    Leukemia; 2007 Jul 22; 21(7):1549-60. PubMed ID: 17460700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.